$Meta Platforms(META.US)$ As I understand, institutions bitchslapped meta for following reasons:
1. Capital Expenditures - Meta is ramping up its investment in AI, raising its 2024 spending forecast to $35 billion to $40 billion, up from $30 billion to $37 billion. They're betting big on future tech.
2. Revenue Forecast - For Q2, Meta expects revenue between $36.5 billion and $39 billion. The midpoint, $37.75 billion, represents an 18% year-o...

$Travere Therapeutic(TVTX.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Insmed(INSM.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phas...

$JPMorgan(JPM.US)$ just out - $TG Therapeutics(TGTX.US)$ BUY PT 25 VA contract Unequivocal  win for TGTX on couple fronts 👍 few details still to be worked out but looks like 40 million a year new durable revenue stream for $TG Therapeutics(TGTX.US)$

1. $ASML Holding(ASML.US)$ | ASML Holding
• Chip Equipment Niche | Photolithography Monopoly
• Enterprise Value | $318.2B
• 2024 Key Metrics | 51x FCF; 34x EBITDA; 1% rev growth
• Competitive Advantage: They stand out as the sole supplier of extreme ultraviolet (EUV) lithography machines, a critical technology for manufacturing the most advanced semiconductor chips. Their market advantage is deeply rooted in this unique offering, which enables the production of smaller, more p...

$Eli Lilly and Co(LLY.US)$  two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

$TG Therapeutics(TGTX.US)$ short interest still trending up - $Viking Therapeutics(VKTX.US)$ - short interest down some

$SPDR S&P Biotech ETF(XBI.US)$ $iShares Biotechnology ETF(IBB.US)$
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.

$Legend Biotech(LEGN.US)$ $Johnson & Johnson(JNJ.US)$
🔔 FDA approves CARVYKTI® label expansion 🎉
⇨ 1st and only BCMA-targeted CAR-T cell therapy
for 2nd-line Tx of multiple myeloma
⇨ based on CARTITUDE-4 study
⇨ 11:0 favorable FDA AdCom votes

$SPDR S&P Biotech ETF(XBI.US)$ $iShares Biotechnology ETF(IBB.US)$
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $iShares 20+ Year Treasury Bond ETF(TLT.US)$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...

$Super Micro Computer(SMCI.US)$
Over the last 36 months, the stock is up 27-fold
Here's why:
AI driven demand - Everywhere you look, companies are investing in AI. While that means different things to different businesses, one thing is consistent. They're virtually all spending more on data-center hardware.
And SMCI is right there to benefit. Super Micro manufactures high performance servers and storage systems. So as companies have expanded their se...